- Home
- CANF vs STRR Comparison
CANF vs STRR Comparison
Compare CANF & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- STRR
- Stock Information
- Founded
- CANF 1994
- STRR 1985
- Country
- CANF Israel
- STRR United States
- Employees
- CANF N/A
- STRR N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CANF Health Care
- STRR Health Care
- Exchange
- CANF Nasdaq
- STRR Nasdaq
- Market Cap
- CANF 14.4M
- STRR 13.3M
- IPO Year
- CANF N/A
- STRR N/A
- Fundamental
- Price
- CANF $2.27
- STRR $4.02
- Analyst Decision
- CANF Strong Buy
- STRR
- Analyst Count
- CANF 2
- STRR 0
- Target Price
- CANF $14.00
- STRR N/A
- AVG Volume (30 Days)
- CANF 136.1K
- STRR 9.3K
- Earning Date
- CANF 11-15-2024
- STRR 11-06-2024
- Dividend Yield
- CANF N/A
- STRR N/A
- EPS Growth
- CANF N/A
- STRR N/A
- EPS
- CANF N/A
- STRR N/A
- Revenue
- CANF $667,000.00
- STRR $47,147,000.00
- Revenue This Year
- CANF $356.93
- STRR $19.97
- Revenue Next Year
- CANF N/A
- STRR $41.50
- P/E Ratio
- CANF N/A
- STRR N/A
- Revenue Growth
- CANF N/A
- STRR N/A
- 52 Week Low
- CANF $1.81
- STRR $3.43
- 52 Week High
- CANF $4.69
- STRR $6.55
- Technical
- Relative Strength Index (RSI)
- CANF 59.89
- STRR 45.04
- Support Level
- CANF $1.87
- STRR $3.89
- Resistance Level
- CANF $2.55
- STRR $4.29
- Average True Range (ATR)
- CANF 0.15
- STRR 0.23
- MACD
- CANF 0.05
- STRR -0.01
- Stochastic Oscillator
- CANF 67.19
- STRR 19.70
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.